Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

Stock Information for Cassava Sciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cassava Sciences Inc.

Cassava Reports Q1 2025 Financials Results, Provides Business Update
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC
Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development
Cassava Sciences Reports 2024 Financial Results and Provides Business Update
Cassava Sciences Licenses Simufilam Method of Treatment Patent
SAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SAVA
SAVA DEADLINE TODAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important February 10 Deadline in Securities Class Action - SAVA

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.